Prenetics Posts 480% Revenue Surge to $92.4M, Affirms $180–200M IM8 Guidance
Prenetics Global reported 2025 revenue surged 480% y/y to $92.4 million, driven by IM8’s $120 million ARR and Q4 revenue of $36.6 million, up 55% q/q. A $70 million Insighta sale boosted liquidity to $171 million and eliminated debt, while 2026 IM8 revenue guidance was set at $180–200 million.
1. 2025 Revenue Surge and IM8 Performance
Prenetics delivered a 480% year-over-year increase in 2025 revenue to $92.4 million, with its flagship IM8 brand achieving an annual recurring revenue of $120 million within a year of launch. Q4 revenue reached $36.6 million, marking a 55% sequential rise, underscoring strong consumer adoption.
2. Asset Divestitures and Strengthened Balance Sheet
The company sold its Insighta stake for $70 million and divested non-core units like ACT Genomics and Europa distribution, bolstering adjusted liquidity to $171 million and eliminating all debt. Prenetics also halted cryptocurrency purchases, retaining a permanent holding of 510 BTC.
3. 2026 Guidance and Subscription Model Pivot
Prenetics reaffirmed IM8 revenue guidance of $180–200 million for 2026, targeting up to $300 million ARR by year-end. A shift toward quarterly subscription plans has already lifted average order value to roughly $233, positioning the business for stable recurring revenue growth.